Edgestream Partners L.P. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 93.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 347 shares of the biopharmaceutical company's stock after selling 4,870 shares during the quarter. Edgestream Partners L.P.'s holdings in Regeneron Pharmaceuticals were worth $365,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. SteelPeak Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Mizuho Securities USA LLC boosted its stake in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after acquiring an additional 51,162 shares during the last quarter. Tri Locum Partners LP grew its holdings in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock worth $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Finally, Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $1,334,000. Hedge funds and other institutional investors own 83.31% of the company's stock.
Analysts Set New Price Targets
REGN has been the topic of several research reports. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. Leerink Partners reaffirmed a "market perform" rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $1,107.29.
Check Out Our Latest Analysis on REGN
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ:REGN traded up $10.10 during trading hours on Friday, hitting $778.00. 813,640 shares of the company's stock traded hands, compared to its average volume of 785,952. The company's fifty day simple moving average is $876.85 and its two-hundred day simple moving average is $1,011.68. The company has a market cap of $85.49 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 2.91 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Recommended Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
